Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance RaisedZacks Investment Research • 07/29/26
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 07/29/26
Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster DrugsBarrons • 07/29/26
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/22/26
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology NationwidePRNewsWire • 07/16/26
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study DataZacks Investment Research • 07/15/26
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 TranscriptSeeking Alpha • 07/14/26
Biogen Wins FDA Approval for Subcutaneous Starter Dose of LeqembiZacks Investment Research • 07/14/26
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of TreatmentPRNewsWire • 07/14/26
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's DiseaseGlobeNewsWire • 07/14/26
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's DiseasePRNewsWire • 07/13/26